How UnitedHealth’s 5-Year Low Set Up a Monster Buy Opportunity

Snapshot: Why We’re Bullish on UNH

Let’s Talk Numbers

The Headlines That Spooked the Market

First, the guidance was yanked. UnitedHealth had previously forecast 2025 earnings between $26.00–$26.50 per share. But citing higher-than-expected costs in Medicare Advantage and a shift in Optum patient profiles, they pulled the plug. That alone would’ve dinged the stock.

But then came the one-two punch.

CEO Andrew Witty unexpectedly stepped down, citing personal reasons. The company quickly reinstated former CEO Stephen Hemsley, a steady hand, but the timing rattled Wall Street.

And just a day later, whispers of a DOJ investigation into Medicare billing exploded. UnitedHealth firmly denied any formal notice — but the damage was done and the stock tanked fast.

“When it rains in a bull market, no one cares,” Shaun David says. “But when it rains during rotation season and a leadership shakeup, investors bring umbrellas and bail.”

The Business Is Still Solid 

The market may be panicking — but the machine hasn’t stopped.

UnitedHealth still generated over $109 billion in quarterly revenue, with Optum alone contributing nearly $55 billion. OptumRx, despite being targeted politically, accounted for over $13.9 billion in Q1 revenue and 16% of company-wide earnings.

“This isn’t some speculative biotech,” Shaun says. “UNH is printing billions in cash, raising dividends, and still gaining members.”

Its vertical integration, paired insurance with PBM, analytics, virtual care, and physician groups — remains unmatched in scale. Even amid noise, UNH is on track for a 2026 growth rebound as it rebalances care costs.

So Why Is Everyone Running?

Because that’s what people do when headlines scream “DOJ” and “CEO quits” on the same day.

But the selling is behavioral, not structural. This is a market that’s punished every whiff of political risk. It dumped Meta on privacy probes. It punished JPMorgan over regulation. And now? It’s nuking UNH over a rumor and a reshuffle.

“Liquidity and sentiment drive stocks in the short term,” Shaun says. “But earnings and scale always win long term. UNH has both.”

Add to that the fact that UNH was a mega-cap Dow component — and indexers had to rebalance aggressively on the way down.

Analyst Views: Still Overwhelmingly Bullish

This may shock you: despite the crash, 22 out of 27 analysts still rate UNH a Buy or Strong Buy. Price targets remain in the $450–$500 range, which  implies nearly 50% upside from current levels.

Even institutions are nibbling. CleaRank’s data shows volume spikes on down days, with long-term accounts increasing exposure.

“They’re not buying the headlines,” Shaun notes. “They’re buying the moat.”

And he’s not alone. Traders who missed UNH in 2020 or 2018 know what this looks like: peak pessimism masking peak potential.

Behavior > Headlines

Let’s take a breath.

Yes — the DOJ is investigating. No — it hasn’t officially charged UNH.

Yes — Witty left suddenly. No — Hemsley isn’t new to the job. He led the company through the 2008 crisis.

Yes — Medicare costs are up. But UNH still dominates the segment and has pricing power heading into 2026.

“This is classic overreaction,” Shaun says. “And that’s exactly when long-term investors make their best buys.”

Insider Buying: CEOs Don’t Spend $25M for Fun

One final detail that most investors missed: the new CEO, Stephen Hemsley, just put his money where his mouth is — buying $25 million worth of UNH stock on May 16, just days after stepping back into the role. He paid an average price of $288.57 per share. CFO John Rex also scooped up $5 million worth. And three UnitedHealth directors followed with additional insider buys totaling $1.6 million.

“Insider buying at this level isn’t a PR move,” says Shaun David. “It’s a signal. Hemsley knows the playbook, he knows the numbers — and he clearly thinks this stock is cheap.”

In a market full of noise, few signals are louder than a CEO betting millions of dollars on his own company.

Our Verdict: This Could Be the Best Entry Point in 5 Years

If you look past the headlines and  zoom out a moment, it’s clear that despite UnitedHealth’s stumble, its foundation hasn’t cracked and remains more solid than ever.

It’s still America’s largest insurer. It still owns Optum, one of the most profitable health-tech machines in the world. And it still generates billions in free cash flow, quarter after quarter.

At 11× forward earnings, a 2.9% dividend, and nearly $50 billion in annual Optum revenue, this stock isn’t broken — it’s on sale.

“If you can tune out the noise and zoom out to the fundamentals,” Shaun concludes, “you’re staring at one of the best asymmetric setups in the entire S&P 500 right now.”

FAQ